Skip to main content

Table 1 Human tissue cohort

From: Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies

Disease n Sex (% male) Age (years) PMI (hrs) NFT Braak stage Thal Phase CERAD NIA-AA LB Braak stage McKeith Criteria
Histology-qualitative
Con 6 66.70% 60–90 24–85 0-IV 0–3 neg-B Low-inter 0 100%-No LB
82 ± 4.5 55.3 ± 9.5 16.6%-0 16.6%-0 83.3%-neg 83.3%- low 100%-0  
   16.6%-I 16.6.%-1 16.6%-B 16.6%-inter   
   33.3%%- II 16.6%-2     
   16.6%-III 50%-3     
   16.6%-IV      
DLB 9 66.70% 72–91 10–99 I–III 0–4 *neg-B Not-inter *6 100%-Neo
    78.2 ± 1.9 55 ± 12.1 11.1%-I 14.3%-0 55.6%-neg 11.1%-not 100%-6  
      89.9%-III 14.3%-1 22.2%-A 55.6%-low   
       14.3%-2 22.2%-B 33.3%- inter   
       14.3%-3     
       42.9%-4     
Histology – pS129 nuclear quantification
Con 12 58.30% 60–95 15–66 0-III 0–5 neg-A Not-inter 0 100%-No LB
81 ± 3.2 42 ± 5.4 25%-0 41.7%-0 91.7%-neg 41.7%-not 100%-0  
   50%-II 25%-1 8.3%-A 50%-low   
   25%-III 8.3%-2   8.3%-inter   
    8.3%-3     
    8.3%-4     
    8.3%-5     
DLB 12 91.60% 71–91 8–98 II–III *0–5 neg-B Not-inter *4–6 16.7%-limbic
78.5 ± 1.7 38.8 ± 8.8 41.7%-II 30%-0 60%-neg 20%-not 12.5%-4 83.3%-Neo
   58.3%-III 10%-1 10%-A 30%-low 87.5%-6  
    10%-2 30%-B 50%-inter   
    20%-3     
    10%-4     
    20%-5     
Western blot
Con 9 55.60% 73–99 5–75 0-III 0–4 neg Not-low 0 100%-No LB
85.3 ± 2.7 31.7 ± 7.4 22.2%-0 22.2%-0 100%-neg 22.2%-not 100%-0  
   11.1%-I 22.2%-1   77.7%-low   
   55.6%-II 11.1%-2     
   11.1%-III 33.3%-3     
    11.1%-4     
DLB 8 75% 68–92 8–99 II–III 03-May neg-B Low-inter 05-Jun 100%-Neo
78.5 ± 3 39.5 ± 11.9 37.5%-II 12.5%-3 62.5%-neg 87.5%-low 25%-5  
   62.5%-III 62.5%-4 25%-A 12.5%- inter 75%–6  
    25%-5 12.5%-B    
Mass spectrometry
Con 3 33.30% 64–99 5–93 I–II 0–1 neg Not-low 0 100%-No LB
81 ± 10.1 41 ± 26 33.3%-I 66.7%-0 100%-neg 66.7%-low 100%-0  
   66.7%-II 33.3%-1   33.3%-inter   
DLB 3 100% 78–81 8–34 III 03-Apr A-B Low-inter 6 100%-Neo
79.7 ± 0.9 22.7 ± 7.7 100%-III 33.3%-3 33.3%-A 33.3%-low 100%-6  
    67.7%-4 67.7%-B 66.7%-inter   
  1. Human cases use for histology, western blot and mass spectrometry. Case are separated by disease classification according to non-diseased controls (Con) and dementia with Lewy bodies (DLB). Case numbers (n), sex, age, post-mortem interval (PMI), neurofibrillary tangle (NFT) Braak stage, Thal phase, Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), the National Institute of Ageing—Alzheimer’s Association (NIA-AA) criteria, Lewy body (LB) Braak stage and McKeith criteria are provided. For age and PMI both range and mean ± SEM are provided. For numerical scores of pathology, range and percentage composition are given. For CERAD scores, negative (neg), A and B reported. For NIA-AA, not, low and intermediate (inter) risk for Alzheimer’s disease. For McKeith criteria, only percentage composition is given, where cases free of LBs (No LB) and neocortical predominate (Neo) are indicated. * = based on available data